Sign in
Enrolling by invitationPhase 3

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

Key facts

Who runs it
Ultragenyx Pharmaceutical Inc
Where
Columbus, United StatesSee the siteAlso in 2 other countries, 3 sites
Status
Enrolling by invitation
Phase
Phase 3
People taking part
41 people, planned
Started
28 Sept 2020
Expected to end
Aug 2027
Type of study
Interventional, 2 groups
Treatments tested
  • No Investigational Product
  • Adjuvant Immunomodulatory (IM) Therapy
Record updated
17 July 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants that have participated in a prior clinical trial in which they received UX111
  • Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule

Who cannot take part

  • Any other situation or medical condition that precludes the participant from undergoing procedures required in this study
  • Planned or current participation in another clinical trial that may confound the safety or efficacy evaluation of UX111 during this study

Where in United States

Also in 2 other countries, 3 sites

  • Nationwide Children's HospitalColumbus, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).

The 2 groups in the trial

  • Cohort AOther group

    Participants who have participated in a prior clinical trial involving the administration of UX111 (rebisufligene etisparvovec) and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IM therapy.

    Treatment: No Investigational Product and Adjuvant Immunomodulatory (IM) Therapy

  • Cohort BOther group

    Participants who have participated in a prior clinical trial involving the administration of UX111 (rebisufligene etisparvovec) and who cannot participate in Cohort A. Participants will partake in a reduced number of assessments, performed either onsite or at home via a combination of telehealth and home healthcare visits.

    Treatment: No Investigational Product

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Long-term Follow-up Study of Patients With MPS IIIA From Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)
Record updated
17 July 2026